Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517403 | 1.00 | AKR1B10 (0.46) | AKR1B10AKR1B1KMT2AMAPTLMNA | |
| SCHEMBL4506546 | 0.87 | AKR1B10 (0.43) | AKR1B10AKR1B1KMT2AMAPTLMNA | |
| SCHEMBL6345437 | 0.86 | GLO1 (0.48) | KMT2AMAPTLMNAKDM4EHSP90AA1 | |
| SCHEMBL6345435 | 0.86 | GLO1 (0.48) | KMT2AMAPTLMNAKDM4EHSP90AA1 | |
| SCHEMBL2424030 | 0.80 | GLO1 (0.65) | KMT2AMAPTLMNAKDM4EHSP90AA1 | |
| SCHEMBL2424031 | 0.80 | GLO1 (0.65) | KMT2AMAPTLMNAKDM4EHSP90AA1 | |
| SCHEMBL15026370 | 0.80 | GLO1 (0.65) | KMT2AMAPTLMNAKDM4EHSP90AA1 | |
| SCHEMBL4512772 | 0.80 | ALDH1A1 (0.53) | KMT2AMAPTLMNAKDM4EHSP90AA1 | |
| SCHEMBL4900705 | 0.80 | ALDH1A1 (0.53) | KMT2AMAPTLMNAKDM4EHSP90AA1 | |
| SCHEMBL5399119 | 0.79 | GLO1 (0.46) | KMT2AMAPTLMNAKDM4EHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070903-A1 | NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES | P2RY10, CACNA1B, CACNA1E | AKR1B10 1981/4885AKR1B1 2103/4885KMT2A 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.